Tiziana Life Sciences Announces Positive Biomarker Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy TLSA?
Tiziana Life Sciences announces positive new biomarker data from a late-breaking poster titled "Nasal foralumab downregulates CSF inflammation and upregulates CSF neuroprotective proteomic pathways which correlate with PBR06-PET imaging in na-SPMS with PIRA," which was presented by investigators from Brigham and Women's Hospital, Boston, MA. Key findings include: Nasal foralumab treatment significantly reduced voxel-wise average PBR06-PET m-GALP z-scores in white matter and global brain regions, confirming decreased microglial activation. CSF proteomics showed downregulation of inflammatory biomarkers and upregulation of neuroprotective proteins. Strong positive correlations were observed between PET m-GALP z-scores and inflammatory CSF proteins. Negative correlations were seen with neuroprotective proteins. These biomarker changes occurred alongside clinical stabilization or improvement, with no serious treatment-related adverse events.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLSA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLSA
About TLSA
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti-IL-6R mAb (TZLS-501), a fully human mAb, binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune and cancer, reducing circulating levels of the IL-6 cytokine. Its oncology product candidate, Milciclib, is a combination therapy for the treatment of refractory solid tumors (being cancers which are non-responsive or become resistant to treatment), especially non-small cell lung cancer (NSCLC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tiziana Life Sciences Publishes Intranasal Foralumab Study, Highlighting Efficacy Potential
- Clinical Study Results: Tiziana Life Sciences' intranasal foralumab clinical study has been published in Neurology Neuroimmunology & Neuroinflammation, confirming the therapy's potential for non-active secondary progressive multiple sclerosis patients, particularly those worsening despite prior treatments.
- Study Design and Findings: The open-label trial evaluated intranasal foralumab in 10 na-SPMS patients, showing improvements in clinical symptoms for several patients, favorable biomarker shifts indicating reduced inflammation, and a well-tolerated safety profile with no major concerns reported.
- Advantages of Delivery Route: The intranasal delivery method aims to engage the immune system through mucosal pathways, potentially offering a safer and more targeted treatment option compared to systemic immunosuppression, which Tiziana positions as a differentiator in autoimmune disease therapy.
- Future Development Plans: With peer-reviewed validation, Tiziana plans to advance intranasal foralumab through further clinical development, expecting top-line data from an ongoing randomized, double-blind, placebo-controlled Phase 2 trial in na-SPMS in the first half of 2026, while exploring broader applications in neuroinflammatory and autoimmune conditions.
See More
Tiziana Life Sciences Closes Direct Offering of 7.04 Million Shares, Raising $8.8 Million
- Successful Financing: Tiziana Life Sciences has closed a direct offering of 7.04 million ordinary shares at $1.25 per share, raising a total of $8.8 million to support its upcoming clinical trials.
- Executive Purchases: CEO Ivor Elrifi purchased 2.4 million shares in this offering, increasing his total holdings to 2.75 million shares, reflecting strong confidence in the company's future.
- Warrant Incentives: Each subscriber will receive a warrant to purchase new ordinary shares at $1.50, potentially generating an additional $10.56 million, which enhances the company's financial flexibility.
- Clinical Trial Advancement: The proceeds from this offering will fund Tiziana's Phase 2 trials for na-SPMS and MSA, expected to provide critical data supporting the company's innovations in neuroimmunotherapy.
See More
Tiziana Life Sciences Closes $8.8 Million Direct Offering of 7.04 Million Shares
- Successful Financing: Tiziana Life Sciences has closed a direct offering of 7.04 million ordinary shares at $1.25 per share, raising a total of $8.8 million to support its upcoming clinical trials.
- Executive Purchases: CEO Ivor Elrifi purchased 2.4 million shares in this offering, increasing his total holdings to 2,757,848 shares, reflecting strong confidence in the company's future prospects.
- Warrant Incentives: Each subscriber will receive a warrant to purchase new ordinary shares at $1.50 until July 16, 2026, potentially generating an additional $10.56 million in gross proceeds for the company.
- Advancing Clinical Trials: The proceeds from this offering will fund Tiziana's Phase 2 trials for na-SPMS and MSA, which are expected to yield significant clinical data, enhancing the market potential of its biopharmaceutical products.
See More
Tiziana Submits 37.4 Patient-Years Safety Report for Foralumab, Highlighting Safety Profile
- Safety Milestone: Tiziana's seventh Development Safety Update Report reveals no serious adverse events after 37.4 patient-years of exposure to foralumab, underscoring its safety in treating neuroinflammatory diseases and enhancing the company's competitive edge in biopharmaceuticals.
- Clinical Experience Accumulation: In the Expanded Access Program, 14 naSPMS patients received foralumab, contributing 30.7 patient-years of exposure, demonstrating the drug's potential and efficacy in clinical applications.
- Treatment Demand Highlighted: The FDA's denial of Sanofi's tolebrutinib application emphasizes the urgent need for safe therapies, positioning Tiziana's findings as a new treatment option that may attract increased investor interest.
- Future Trial Outlook: Tiziana's Phase 2 trial is set to read out in 2026, and if successful, will further solidify its leadership in neurodegenerative disease treatment, driving long-term growth for the company.
See More
Tiziana Submits 37.4 Patient-Years Safety Report for Intranasal Foralumab
- Safety Milestone: Tiziana reports no serious adverse events after 37.4 patient-years of cumulative exposure to intranasal foralumab, demonstrating its favorable safety profile in treating neuroinflammatory diseases, which could provide a significant therapeutic option in the future.
- Clinical Experience Accumulation: In the Expanded Access Program, 14 patients with non-active secondary progressive multiple sclerosis received nasal foralumab, contributing 30.7 patient-years of exposure, further validating the drug's tolerability and efficacy.
- Research Progress: Tiziana's Phase 2 clinical trial is expected to read out results in 2026, and if successful, it will lay the groundwork for the market introduction of intranasal foralumab, enhancing the company's competitiveness in the biopharmaceutical sector.
- Market Demand Opportunity: The FDA's denial of Sanofi's tolebrutinib highlights the need for safe therapeutic options, and Tiziana's research findings may gain increased attention in this context, potentially boosting market acceptance of its products.
See More
Tiziana Rings Nasdaq Closing Bell Celebrating Foralumab Advancements
- Milestone Celebration: Tiziana Life Sciences' Executive Chairman Gabriele Cerrone rings the Nasdaq Closing Bell in New York, celebrating the company's ongoing advancements in innovative treatments, highlighting the dedication of the team and investors.
- Clinical Trial Progress: The company successfully dosed the first patient in its Phase 2 Alzheimer's trial, marking a significant advancement in the treatment of neurodegenerative diseases, which is expected to drive future market opportunities.
- Unique Therapeutic Advantage: Tiziana's intranasal foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating improved safety and tolerability compared to traditional intravenous methods, potentially transforming the treatment landscape for neuroinflammatory and neurodegenerative diseases.
- Innovation Potential: The company's alternative immunotherapy technology has been patented with several applications pending, which is expected to provide broad pipeline applications in the future, further solidifying its leading position in the biopharmaceutical sector.
See More
Tiziana Life Sciences Publishes Intranasal Foralumab Study, Highlighting Efficacy Potential
- Clinical Study Results: Tiziana Life Sciences' intranasal foralumab clinical study has been published in Neurology Neuroimmunology & Neuroinflammation, confirming the therapy's potential for non-active secondary progressive multiple sclerosis patients, particularly those worsening despite prior treatments.
- Study Design and Findings: The open-label trial evaluated intranasal foralumab in 10 na-SPMS patients, showing improvements in clinical symptoms for several patients, favorable biomarker shifts indicating reduced inflammation, and a well-tolerated safety profile with no major concerns reported.
- Advantages of Delivery Route: The intranasal delivery method aims to engage the immune system through mucosal pathways, potentially offering a safer and more targeted treatment option compared to systemic immunosuppression, which Tiziana positions as a differentiator in autoimmune disease therapy.
- Future Development Plans: With peer-reviewed validation, Tiziana plans to advance intranasal foralumab through further clinical development, expecting top-line data from an ongoing randomized, double-blind, placebo-controlled Phase 2 trial in na-SPMS in the first half of 2026, while exploring broader applications in neuroinflammatory and autoimmune conditions.
See More
Tiziana Life Sciences Closes Direct Offering of 7.04 Million Shares, Raising $8.8 Million
- Successful Financing: Tiziana Life Sciences has closed a direct offering of 7.04 million ordinary shares at $1.25 per share, raising a total of $8.8 million to support its upcoming clinical trials.
- Executive Purchases: CEO Ivor Elrifi purchased 2.4 million shares in this offering, increasing his total holdings to 2.75 million shares, reflecting strong confidence in the company's future.
- Warrant Incentives: Each subscriber will receive a warrant to purchase new ordinary shares at $1.50, potentially generating an additional $10.56 million, which enhances the company's financial flexibility.
- Clinical Trial Advancement: The proceeds from this offering will fund Tiziana's Phase 2 trials for na-SPMS and MSA, expected to provide critical data supporting the company's innovations in neuroimmunotherapy.
See More
Tiziana Life Sciences Closes $8.8 Million Direct Offering of 7.04 Million Shares
- Successful Financing: Tiziana Life Sciences has closed a direct offering of 7.04 million ordinary shares at $1.25 per share, raising a total of $8.8 million to support its upcoming clinical trials.
- Executive Purchases: CEO Ivor Elrifi purchased 2.4 million shares in this offering, increasing his total holdings to 2,757,848 shares, reflecting strong confidence in the company's future prospects.
- Warrant Incentives: Each subscriber will receive a warrant to purchase new ordinary shares at $1.50 until July 16, 2026, potentially generating an additional $10.56 million in gross proceeds for the company.
- Advancing Clinical Trials: The proceeds from this offering will fund Tiziana's Phase 2 trials for na-SPMS and MSA, which are expected to yield significant clinical data, enhancing the market potential of its biopharmaceutical products.
See More
Tiziana Submits 37.4 Patient-Years Safety Report for Foralumab, Highlighting Safety Profile
- Safety Milestone: Tiziana's seventh Development Safety Update Report reveals no serious adverse events after 37.4 patient-years of exposure to foralumab, underscoring its safety in treating neuroinflammatory diseases and enhancing the company's competitive edge in biopharmaceuticals.
- Clinical Experience Accumulation: In the Expanded Access Program, 14 naSPMS patients received foralumab, contributing 30.7 patient-years of exposure, demonstrating the drug's potential and efficacy in clinical applications.
- Treatment Demand Highlighted: The FDA's denial of Sanofi's tolebrutinib application emphasizes the urgent need for safe therapies, positioning Tiziana's findings as a new treatment option that may attract increased investor interest.
- Future Trial Outlook: Tiziana's Phase 2 trial is set to read out in 2026, and if successful, will further solidify its leadership in neurodegenerative disease treatment, driving long-term growth for the company.
See More
Tiziana Submits 37.4 Patient-Years Safety Report for Intranasal Foralumab
- Safety Milestone: Tiziana reports no serious adverse events after 37.4 patient-years of cumulative exposure to intranasal foralumab, demonstrating its favorable safety profile in treating neuroinflammatory diseases, which could provide a significant therapeutic option in the future.
- Clinical Experience Accumulation: In the Expanded Access Program, 14 patients with non-active secondary progressive multiple sclerosis received nasal foralumab, contributing 30.7 patient-years of exposure, further validating the drug's tolerability and efficacy.
- Research Progress: Tiziana's Phase 2 clinical trial is expected to read out results in 2026, and if successful, it will lay the groundwork for the market introduction of intranasal foralumab, enhancing the company's competitiveness in the biopharmaceutical sector.
- Market Demand Opportunity: The FDA's denial of Sanofi's tolebrutinib highlights the need for safe therapeutic options, and Tiziana's research findings may gain increased attention in this context, potentially boosting market acceptance of its products.
See More
Tiziana Rings Nasdaq Closing Bell Celebrating Foralumab Advancements
- Milestone Celebration: Tiziana Life Sciences' Executive Chairman Gabriele Cerrone rings the Nasdaq Closing Bell in New York, celebrating the company's ongoing advancements in innovative treatments, highlighting the dedication of the team and investors.
- Clinical Trial Progress: The company successfully dosed the first patient in its Phase 2 Alzheimer's trial, marking a significant advancement in the treatment of neurodegenerative diseases, which is expected to drive future market opportunities.
- Unique Therapeutic Advantage: Tiziana's intranasal foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating improved safety and tolerability compared to traditional intravenous methods, potentially transforming the treatment landscape for neuroinflammatory and neurodegenerative diseases.
- Innovation Potential: The company's alternative immunotherapy technology has been patented with several applications pending, which is expected to provide broad pipeline applications in the future, further solidifying its leading position in the biopharmaceutical sector.
See More
